Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours ยท Estimated delivery Oct 28 - Nov 2
Additionally, GLP-1 RAs with established CV benefitsspecifically liraglutide, subcutaneous semaglutide, dulaglutide, and efpeglenatideare recommended for patients with T2DM and ASCVD to reduce CV events, regardless of baseline or target HbA1c levels or concurrent glucose-lowering therapy (Class I, LoE A)
Additionally, a 2024 study in Diabetes Epidemiology and Management found that oral semaglutide reduced hemoglobin A1C by an average of 3.1%
It triggers melanin production in areas exposed to the sun, like the face, legs, neck, or arms
Suitable for use under guidance as part of ongoing care
People with prediabetes, diabetes, or family history of diabetes should be particularly vigilant
US$ 23.12
US$ 28.21
US$ 27.51
US$ 20.50
